Valuation: Microbio Co., Ltd.

Capitalization 1.09TCr 34Cr 30Cr 28Cr 26Cr 48Cr 3.11TCr 51Cr 317.91Cr 125.09Cr 1.49TCr 129.24Cr 126.6Cr 5.46TCr P/E ratio 2023
-23.9x
P/E ratio 2024 -17.6x
Enterprise value 894.44Cr 28Cr 24Cr 23Cr 21Cr 39Cr 2.56TCr 42Cr 261.32Cr 102.83Cr 1.22TCr 106.24Cr 104.07Cr 4.49TCr EV / Sales 2023
15.9x
EV / Sales 2024 10.1x
Free-Float
66.98%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
11/11 Microbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
07/25/07 Microbio Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
11/25/11 Microbio Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
17/25/17 Microbio Announces Promising Results Of MS-20 As Add-On Therapy For Ulcerative Colitis RE
17/25/17 Microbio Co., Ltd. Announces Promising Results of MS-20 as an Add-on Therapy for Ulcerative Colitis CI
10/25/10 Microbio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
16/24/16 Microbio Co., Ltd. Announces Promising Results of MS-20 in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer CI
13/24/13 Microbio Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
08/24/08 Microbio Co., Ltd. Announces SNS812 Phase 2 Study Demonstrated Statistical Significance in Treating Covid-19 Based on Its Safety, Precision and Broad-Spectrum Efficacy by Its Subsidiary Microbio Co.,Ltd CI
12/24/12 Microbio Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
31/24/31 Microbio Co., Ltd. Announces the Finding on MS-20 Combined with Anti-PD1 Antibody Enhancing the Cancer Treatment Response CI
11/24/11 Microbio Co., Ltd. Announces Change of the General Manager CI
30/24/30 Microbio Co., Ltd. Announces Change of Remuneration Committee CI
More news
1 day+1.67%
1 week+10.34%
Current month+15.41%
1 month+11.49%
3 months-3.39%
6 months-8.37%
Current year+15.41%
More quotes
1 week 20.05
Extreme 20.05
21.55
1 month 17.9
Extreme 17.9
21.55
Current year 17.9
Extreme 17.9
21.55
1 year 17.9
Extreme 17.9
35.65
3 years 17.9
Extreme 17.9
63.69
5 years 17.9
Extreme 17.9
70.65
10 years 8.41
Extreme 8.4107
115.15
More quotes
Manager TitleAgeSince
Chief Executive Officer - 20/12/2021
Director of Finance/CFO - 01/03/2015
Chief Tech/Sci/R&D Officer - 01/07/2008
Director TitleAgeSince
Director/Board Member 73 14/02/2011
Director/Board Member 86 14/02/2011
Director/Board Member 64 29/05/2006
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.67%+10.34%-30.23%-59.25% 39Cr
+1.50%-1.00%+16.41%+34.94% 1.11TCr
-4.95%+0.60%+52.70%+410.57% 843.78Cr
+0.57%+1.55%+7.25%-49.01% 296.69Cr
+2.44%-1.78%-66.59%-9.93% 281.14Cr
+0.76%+2.42%-35.87%-41.51% 194.32Cr
-1.51%-2.49%+37.16%-11.43% 174.07Cr
-0.38%-0.58% - - 166.59Cr
+4.97%+13.70%+160.22%+1.34% 164.16Cr
+1.67%-0.12%+28.51%+19.19% 108.03Cr
Average +0.23%+1.70%+18.84%+32.77% 337.76Cr
Weighted average by Cap. -0.44%+0.30%+22.98%+111.43%
See all sector performances

Financials

2023 2024
Net sales 159.14Cr 5.04Cr 4.34Cr 4.05Cr 3.76Cr 7Cr 455.45Cr 7.51Cr 46Cr 18Cr 217.73Cr 19Cr 19Cr 798.77Cr 172.29Cr 5.46Cr 4.7Cr 4.38Cr 4.08Cr 7.58Cr 493.07Cr 8.13Cr 50Cr 20Cr 235.72Cr 20Cr 20Cr 864.75Cr
Net income -117.99Cr -3.74Cr -3.22Cr -3Cr -2.79Cr -5.19Cr -337.67Cr -5.57Cr -34Cr -14Cr -161.43Cr -14Cr -14Cr -592.22Cr -110.08Cr -3.49Cr -3Cr -2.8Cr -2.6Cr -4.84Cr -315.04Cr -5.2Cr -32Cr -13Cr -150.61Cr -13Cr -13Cr -552.53Cr
Net Debt -301.75Cr -9.56Cr -8.23Cr -7.67Cr -7.14Cr -13Cr -863.59Cr -14Cr -88Cr -35Cr -412.85Cr -36Cr -35Cr -1.51TCr -193.67Cr -6.13Cr -5.28Cr -4.92Cr -4.58Cr -8.52Cr -554.27Cr -9.14Cr -57Cr -22Cr -264.98Cr -23Cr -23Cr -972.1Cr
More financial data * Estimated data
Logo Microbio Co., Ltd.
Microbio Co., Ltd. is a Taiwan-based company primarily engaged in the research, development, manufacture, distribution and wholesales of healthcare food products and pharmaceuticals. The Company provides fermentation products, including Tien Chun Bao (TCB) oral solutions; herbal products, including LeeHerb series products, as well as organic foods, including vegetables, fruits, nuts, pastry, seasonings, organic meals and others. In addition, it provides new medicines, including anticancer medicines, medicines for hepatitis, allergy, rheumatoid arthritis and others. The Company mainly distributes its products mainly within domestic market.
Employees
-
More about the company
Date Price Change Volume
15/26/15 21.35 NT$ +1.67% 22,61,265
14/26/14 21.00 NT$ +2.19% 29,79,542
13/26/13 20.55 NT$ +0.98% 26,86,922
12/26/12 20.35 NT$ +0.25% 29,44,963
09/26/09 20.30 NT$ +4.91% 73,81,311

End-of-day quote Taipei Exchange, January 15, 2026

More quotes